Vixiar Medical Raises $1.5 Million in Additional Financing

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

Vixiar Medical, Inc., a privately held Maryland company dedicated to the development of non-invasive devices and systems for monitoring cardiopulmonary diseases, announced today that it closed its most recent financing of $1.5 million from new and existing investors. Proceeds will be used to complete an ongoing clinical trial and to prepare regulatory submissions.

“We are pleased to welcome new investors to this round and with the continuing commitment from existing investors,” said Vixiar CEO, Kevin Thibodeau. “Heart failure is a large and growing global concern and there is currently a lack of non-invasive, point-of-care technologies for addressing the major problem of costly hospitalizations and readmissions. Our technology offers a rapid, non-invasive, cost-effective device designed to be used across the continuum of care including hospitals, physician offices, skilled nursing facilities and patient homes.”

New investors joining in this round included Emerald Development Managers, MMG Opportunities and several individual investors. Existing investors included The Maryland Technology Development Corporation (TEDCO) through its seed fund, the Abell Foundation, individual investors and management.

“We believe Vixiar’s platform offers compelling advantages over the competition and addresses a huge unmet need in heart failure monitoring,” stated Neil Cohen, Chairman of Emerald Development Managers. “We are also pleased that the technology was invented and extensively researched by faculty at Johns Hopkins.”

“We have been pleased with the Vixiar team’s progress and look forward to seeing them meet additional milestones as a Baltimore City-headquartered medical device company,” added Eileen O’Rourke, CFO at the Abell Foundation.



Subscribe to Medical Device News Magazine

Related Articles